Difference between revisions of "Transformation of 15-Keto-PGE2 to 13,14-Dihydro-15-Keto-PGE2"
(→Parameters) |
(→Parameters) |
||
Line 122: | Line 122: | ||
pH:7 | pH:7 | ||
| <ref name="Bothwell1982”>[http://jpet.aspetjournals.org/content/220/2/229.long W. Bothwell, "A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics" Journal of Pharmacology and Experimental Therapeutics February 1982, 220 (2) 229-235]</ref> | | <ref name="Bothwell1982”>[http://jpet.aspetjournals.org/content/220/2/229.long W. Bothwell, "A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics" Journal of Pharmacology and Experimental Therapeutics February 1982, 220 (2) 229-235]</ref> | ||
+ | |} | ||
+ | |||
+ | {|class="wikitable" | ||
+ | |+ style="text-align: left;" | Vmax | ||
+ | ! Value | ||
+ | ! Units | ||
+ | ! Species | ||
+ | ! Notes | ||
+ | ! Reference | ||
+ | |- | ||
+ | | 159.23 ± 0.71 | ||
+ | | nmol min-1 mg-1 | ||
+ | | Human | ||
+ | |Method: In vitro | ||
+ | Organism: Human | ||
+ | Expression vector: E.coli | ||
+ | Enzyme: PTGR2 | ||
+ | pH: 7.5 | ||
+ | Temperature: 37 ◦C | ||
+ | Substrate: 15-Keto-PGE2 | ||
+ | | <ref name="Wu2008"> [https://www.ncbi.nlm.nih.gov/pubmed/19000823 Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2, Structure. 2008 Nov 12;16(11):1714-23. doi: 10.1016/j.str.2008.09.007.]</ref> | ||
+ | |- | ||
+ | | 66.73 ± 1.36 | ||
+ | | nmol min-1 mg-1 | ||
+ | | Human | ||
+ | |Method: In vitro | ||
+ | Organism: Human | ||
+ | Expression vector: E.coli | ||
+ | Enzyme: PTGR2 | ||
+ | pH: 7.5 | ||
+ | Temperature: 37 ◦C | ||
+ | Substrate: NADPH | ||
+ | | <ref name="Wu2008"> [https://www.ncbi.nlm.nih.gov/pubmed/19000823 Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2, Structure. 2008 Nov 12;16(11):1714-23. doi: 10.1016/j.str.2008.09.007.]</ref> | ||
+ | |- | ||
|} | |} |
Revision as of 10:43, 13 March 2017
Reaction
Chemical equation
Rate equation
Parameters
Value | Units | Species | Notes | Reference |
---|---|---|---|---|
0.01121 ± 0.00014 | mM | Human | Method: In vitro
Organism: Human Expression vector: E.coli Enzyme: PTGR2 pH: 7.5 Temperature: 37 ◦C Substrate: 15-Keto-PGE2 "For determining the KM and Vmax values for NADPH, 15-keto-PGE2 at a final concentration of 200 mM was used with different concentrations of NADPH (0–60 mM)." |
[1] |
0.01587 ± 0.00171 | mM | Human | Method: In vitro
Organism: Human Expression vector: E.coli Enzyme: e PTGR2 pH: 7.5 Temperature: 37 ◦C Substrate: NADPH "For determining the KM and Vmax values for NADPH, 15-keto-PGE2 at a final concentration of 200 mM was used with different concentrations of NADPH (0–60 mM)." |
[1] |
Value | Units | Species | Notes | Reference |
---|---|---|---|---|
X | Y | Z | A | B |
Value | Units | Species | Notes | Reference |
---|---|---|---|---|
X | Y | Z | A | B |
Value | Units | Species | Notes | Reference |
---|---|---|---|---|
X | Y | Z | A | B |
Value | Units | Species | Notes | Reference |
---|---|---|---|---|
9.9 +/-0.2 | minutes | Dog | In vivo
Temperature:37 pH:7 |
[2] |
Value | Units | Species | Notes | Reference |
---|---|---|---|---|
159.23 ± 0.71 | nmol min-1 mg-1 | Human | Method: In vitro
Organism: Human Expression vector: E.coli Enzyme: PTGR2 pH: 7.5 Temperature: 37 ◦C Substrate: 15-Keto-PGE2 |
[1] |
66.73 ± 1.36 | nmol min-1 mg-1 | Human | Method: In vitro
Organism: Human Expression vector: E.coli Enzyme: PTGR2 pH: 7.5 Temperature: 37 ◦C Substrate: NADPH |
[1] |
- ↑ 1.0 1.1 1.2 1.3 Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2, Structure. 2008 Nov 12;16(11):1714-23. doi: 10.1016/j.str.2008.09.007.
- ↑ W. Bothwell, "A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics" Journal of Pharmacology and Experimental Therapeutics February 1982, 220 (2) 229-235